USANA Health Sciences (NYSE:USNA) Price Target Cut to $46.00

USANA Health Sciences (NYSE:USNA) had its target price reduced by research analysts at DA Davidson from $48.00 to $46.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has a “neutral” rating on the stock. DA Davidson’s price objective suggests a potential upside of 2.06% from the stock’s current price. DA Davidson also issued estimates for USANA Health Sciences’ Q2 2024 earnings at $0.68 EPS.

Separately, StockNews.com raised USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 12th.

USANA Health Sciences Stock Performance

NYSE:USNA opened at $45.07 on Tuesday. USANA Health Sciences has a 1 year low of $41.45 and a 1 year high of $69.60. The stock has a market cap of $865.34 million, a price-to-earnings ratio of 14.04, a PEG ratio of 1.38 and a beta of 0.94. The business has a fifty day moving average of $46.42 and a 200-day moving average of $48.05.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings results on Tuesday, February 6th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.52 by $0.35. USANA Health Sciences had a return on equity of 12.80% and a net margin of 6.88%. The company had revenue of $221.08 million during the quarter, compared to analysts’ expectations of $206.70 million. On average, equities research analysts predict that USANA Health Sciences will post 2.75 EPS for the current year.

Insider Activity at USANA Health Sciences

In related news, CFO G Doug Iiekking sold 5,198 shares of the firm’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $44.76, for a total transaction of $232,662.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Chairman Kevin Guest sold 11,011 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $49.00, for a total value of $539,539.00. Following the completion of the transaction, the chairman now owns 10,491 shares in the company, valued at approximately $514,059. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO G Doug Iiekking sold 5,198 shares of the stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $44.76, for a total value of $232,662.48. The disclosure for this sale can be found here. Insiders sold 34,286 shares of company stock valued at $1,634,010 over the last 90 days. 0.33% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On USANA Health Sciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. CWM LLC lifted its stake in USANA Health Sciences by 21.8% in the 1st quarter. CWM LLC now owns 1,543 shares of the company’s stock worth $75,000 after acquiring an additional 276 shares in the last quarter. New York State Common Retirement Fund lifted its stake in USANA Health Sciences by 1.2% in the 4th quarter. New York State Common Retirement Fund now owns 24,500 shares of the company’s stock worth $1,313,000 after acquiring an additional 279 shares in the last quarter. Swiss National Bank lifted its stake in USANA Health Sciences by 1.2% in the 3rd quarter. Swiss National Bank now owns 25,500 shares of the company’s stock worth $1,495,000 after acquiring an additional 300 shares in the last quarter. Rhumbline Advisers lifted its stake in USANA Health Sciences by 1.4% in the 3rd quarter. Rhumbline Advisers now owns 34,942 shares of the company’s stock worth $2,048,000 after acquiring an additional 496 shares in the last quarter. Finally, Strs Ohio lifted its stake in USANA Health Sciences by 4.8% in the 3rd quarter. Strs Ohio now owns 10,900 shares of the company’s stock worth $638,000 after acquiring an additional 500 shares in the last quarter. Institutional investors and hedge funds own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.